Scholarlink

<p>Uterine sarcoma is an aggressive malignancy that is difficult to distinguish from benign leiomyomas pre-operatively. This study aimed to identify circulating biomarkers to improve differential diagnosis and prognostication. The serum and tissue levels of growth differentiation factor-15 (GDF15), progranulin (PGN), and osteopontin (OPN) were measured in patients with uterine sarcoma (n = 38) and leiomyoma (n = 67). The levels were correlated with diagnosis and patient survival. The serum and tissue levels of GDF15 and OPN were significantly higher in uterine sarcomas than in leiomyomas (<i>p</i> &lt; 0.001). High GDF15 levels were associated with significantly poorer progression-free survival (PFS) (<i>p</i> &lt; 0.001). In a multivariate analysis including established markers cancer antigen 125 (CA125) and lactate dehydrogenase (LDH), only GDF15 remained an independent predictor of PFS [hazard ratio (HR) 3.01, 95% confidence interval (CI) 1.04–8.67, <i>p</i> = 0.042]. The prognostic power of GDF15 was confirmed by an analysis that excluded carcinosarcomas. GDF15 and OPN are promising biomarkers for pre-operatively differentiation of uterine sarcoma from leiomyoma. Furthermore, GDF15 is a strong, independent prognostic factor for PFS in patients with uterine sarcoma and has the potential to improve diagnostic accuracy and clinical management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Diagnostic and prognostic values of circulating growth differentiation factor-15 and osteopontin in uterine sarcoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月19日

查看全文
  • Hideaki Tsuyoshi,
  • Tetsuya Mizutani,
  • Masaya Uno,
  • Tomoyasu Kato,
  • Makoto Orisaka,
  • Yoshio Yoshida

摘要

Uterine sarcoma is an aggressive malignancy that is difficult to distinguish from benign leiomyomas pre-operatively. This study aimed to identify circulating biomarkers to improve differential diagnosis and prognostication. The serum and tissue levels of growth differentiation factor-15 (GDF15), progranulin (PGN), and osteopontin (OPN) were measured in patients with uterine sarcoma (n = 38) and leiomyoma (n = 67). The levels were correlated with diagnosis and patient survival. The serum and tissue levels of GDF15 and OPN were significantly higher in uterine sarcomas than in leiomyomas (p < 0.001). High GDF15 levels were associated with significantly poorer progression-free survival (PFS) (p < 0.001). In a multivariate analysis including established markers cancer antigen 125 (CA125) and lactate dehydrogenase (LDH), only GDF15 remained an independent predictor of PFS [hazard ratio (HR) 3.01, 95% confidence interval (CI) 1.04–8.67, p = 0.042]. The prognostic power of GDF15 was confirmed by an analysis that excluded carcinosarcomas. GDF15 and OPN are promising biomarkers for pre-operatively differentiation of uterine sarcoma from leiomyoma. Furthermore, GDF15 is a strong, independent prognostic factor for PFS in patients with uterine sarcoma and has the potential to improve diagnostic accuracy and clinical management.